Cargando…
Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events
BACKGROUND: Elevated plasma ammonia is central to the pathogenesis of hepatic encephalopathy. Sodium phenylacetate or glycerol phenylbutyrate is approved for urea cycle disorders, but limited clinical data are available for hepatic encephalopathy. Phenylacetic acid (PAA) plasma exposure has been rep...
Autores principales: | Wang, Xiaofeng, Tseng, Jack, Mak, Carmen, Poola, Nagaraju, Vilchez, Regis A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613126/ https://www.ncbi.nlm.nih.gov/pubmed/34125423 http://dx.doi.org/10.1007/s40262-021-01047-5 |
Ejemplares similares
-
Population Pharmacokinetic Analysis to Assist Dose Selection of the l-Ornithine Salt of Phenylacetic Acid
por: Wang, Xiaofeng, et al.
Publicado: (2021) -
Urine Phenylacetylglutamine Determination in Patients with Hyperphenylalaninemia
por: Andrade, Fernando, et al.
Publicado: (2021) -
Phenylacetylglutamine, a Novel Biomarker in Acute Ischemic Stroke
por: Yu, Fang, et al.
Publicado: (2021) -
Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure
por: Zong, Xiao, et al.
Publicado: (2022) -
Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
por: Zhang, Zhendong, et al.
Publicado: (2023)